|
|
Exchange: |
New York Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
289,870,000 |
Market
Cap: |
67.67(B) |
Last
Volume: |
918,580 |
Avg
Vol: |
1,403,311 |
52
Week Range: |
$230.48 - $283.59 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
|
S&P 500 |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 224 |
Guru Rank Value : 5.4 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Becton, Dickinson and Company is a medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. Co.'s business segments are: BD Medical, which produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings; BD Life Sciences, which provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers; and BD Interventional, which provides vascular, urology, oncology and surgical products.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
282 |
3,677 |
9,258 |
39,261 |
Total Sell Value |
$67,198 |
$869,357 |
$2,420,786 |
$10,261,828 |
Total People Sold |
1 |
3 |
5 |
7 |
Total Sell Transactions |
1 |
3 |
7 |
14 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Polen Thomas E Jr |
Executive Vice President |
|
2018-11-19 |
4 |
OE |
$134.73 |
$1,578,766 |
D/D |
11,718 |
23,896 |
|
- |
|
Bodner Charles R |
SVP Corp Fin Chief Acct Office |
|
2018-11-16 |
4 |
S |
$245.82 |
$511,328 |
D/D |
(2,080) |
1,047 |
|
- |
|
Bodner Charles R |
SVP Corp Fin Chief Acct Office |
|
2018-11-16 |
4 |
D |
$245.84 |
$336,801 |
D/D |
(1,370) |
3,127 |
|
- |
|
Bodner Charles R |
SVP Corp Fin Chief Acct Office |
|
2018-11-16 |
4 |
OE |
$134.73 |
$336,825 |
D/D |
2,500 |
4,497 |
|
- |
|
Forlenza Vincent A |
Chairman, CEO and President |
|
2018-11-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
530 |
212,267 |
|
- |
|
Forlenza Vincent A |
Chairman, CEO and President |
|
2018-11-15 |
4 |
GD |
$0.00 |
$0 |
D/D |
530 |
193,780 |
|
- |
|
Forlenza Vincent A |
Chairman, CEO and President |
|
2018-11-14 |
4 |
S |
$235.78 |
$3,182,558 |
D/D |
(13,498) |
194,310 |
|
- |
|
Forlenza Vincent A |
Chairman, CEO and President |
|
2018-11-14 |
4 |
D |
$235.78 |
$1,533,042 |
D/D |
(6,502) |
222,381 |
|
- |
|
Forlenza Vincent A |
Chairman, CEO and President |
|
2018-11-14 |
4 |
OE |
$76.64 |
$1,532,800 |
D/D |
20,000 |
228,883 |
|
- |
|
Mas Ribo Alberto |
EVP and Pres, Life Sciences |
|
2018-11-14 |
4 |
S |
$237.01 |
$1,073,655 |
D/D |
(4,530) |
14,596 |
|
- |
|
Forlenza Vincent A |
Chairman, CEO and President |
|
2018-11-13 |
4 |
S |
$237.61 |
$4,007,530 |
D/D |
(16,866) |
208,883 |
|
- |
|
Forlenza Vincent A |
Chairman, CEO and President |
|
2018-11-13 |
4 |
D |
$237.61 |
$1,871,416 |
D/D |
(7,876) |
225,749 |
|
- |
|
Forlenza Vincent A |
Chairman, CEO and President |
|
2018-11-13 |
4 |
OE |
$75.63 |
$1,871,237 |
D/D |
24,742 |
233,625 |
|
- |
|
Lim James C |
Executive Vice President |
|
2018-11-08 |
4 |
S |
$242.36 |
$1,257,606 |
D/D |
(5,189) |
13,318 |
|
- |
|
Ring Timothy M |
Director |
|
2018-11-07 |
4 |
S |
$237.07 |
$9,956,940 |
D/D |
(42,000) |
93,688 |
|
- |
|
Khichi Samrat S. |
EVP and General Counsel |
|
2018-08-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
48 |
31,337 |
|
- |
|
Tozzi William A |
EVP Pres Interventional |
|
2018-07-02 |
4 |
A |
$0.00 |
$0 |
D/D |
4,008 |
12,830 |
|
- |
|
Ring Timothy M |
Director |
|
2018-07-02 |
4 |
D |
$238.90 |
$8,361,500 |
D/D |
(35,000) |
135,688 |
|
- |
|
Burzik Catherine M |
Director |
|
2018-06-22 |
4 |
B |
$239.01 |
$10,755 |
D/D |
45 |
10,022 |
2.39 |
- |
|
Kaltenbach Patrick |
EVP & Pres Life Sciences |
|
2018-06-01 |
4 |
A |
$0.00 |
$0 |
D/D |
2,533 |
2,533 |
|
- |
|
Conroy Alexandre |
Executive Vice President |
|
2018-05-21 |
4 |
S |
$228.74 |
$4,604,079 |
D/D |
(20,128) |
26,436 |
|
- |
|
Conroy Alexandre |
Executive Vice President |
|
2018-05-21 |
4 |
D |
$228.74 |
$2,237,535 |
D/D |
(9,782) |
32,435 |
|
- |
|
Conroy Alexandre |
Executive Vice President |
|
2018-05-21 |
4 |
OE |
$72.12 |
$2,234,994 |
D/D |
29,910 |
35,436 |
|
- |
|
Shabshab Nabil |
Executive Vice President |
|
2018-05-11 |
4 |
S |
$226.10 |
$2,308,255 |
D/D |
(10,209) |
7,811 |
|
- |
|
Shabshab Nabil |
Executive Vice President |
|
2018-05-11 |
4 |
D |
$226.10 |
$1,851,985 |
D/D |
(8,191) |
14,928 |
|
- |
|
1851 Records found
|
|
Page 19 of 75 |
|
|